RETRACTED ARTICLE: The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC
Authors:
- 18 July 2018
- journal article
- retracted article
- Published by Taylor & Francis in Cell Cycle
- Vol. 17 (14) , 1772-1783
Abstract
Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib has exhibited notable clinical efficacy in non-small cell lung cancer (NSCLC) patients. However, its therapeutic efficacy is ultimately limited by the development of gefitinib resistance. The present study aimed to investigate the effects of the long non-coding RNA, RHPN1-AS1 on gefitinib resistance in NSCLC and explore the underlying mechanisms. In this study, RHPN1-AS1 was observed to be downregulated in gefitinib resistant patients and NSCLC cell lines. Besides, decreased expression of RHPN1-AS1 was found to be associated with poor prognosis of NSCLC patients. RHPN1-AS1 knockdown conferred gefitinib resistance to gefitinib sensitive NSCLC cells, whereas the overexpression of RHPN1-AS1 sensitized gefitinib resistant NSCLC cells to gefitinib treatment. Mechanistically, RHPN1-AS1 was found to positively regulate the expression of TNFSF12 by directly interacting with miR-299-3p. Collectively, RHPN1-AS1 modulates gefitinib resistance through miR-299-3p/TNFSF12 pathway in NSCLC. Our findings indicate that RHPN1-AS1 may serve as not only a prognostic biomarker for gefitinib resistance but also as a promising therapeutic biomarker and target for the treatment of NSCLC patients.Keywords
Funding Information
- Natural Science Foundation of Liaoning Province (2017225035)
This publication has 26 references indexed in Scilit:
- Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cellsToxicology and Applied Pharmacology, 2017
- MicroRNA-299-3p suppresses proliferation and invasion by targeting VEGFA in human colon carcinomaBiomedicine & Pharmacotherapy, 2017
- miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-MetScientific Reports, 2017
- The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma ProgressionInternational Journal of Molecular Sciences, 2017
- Role of epidermal growth factor receptor in lung cancer and targeted therapies2017
- The bright side of dark matter: lncRNAs in cancerJournal of Clinical Investigation, 2016
- Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancerOncotarget, 2016
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trialThe Lancet Oncology, 2015
- MicroRNA 299-3p modulates replicative senescence in endothelial cellsPhysiological Genomics, 2013
- Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidenceLung Cancer, 2011